Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Blood (2024) 144 (Supplement 1): 342.

https://doi.org/10.1182/blood-2024-200262

Published: 2024

Journal Articles

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Paul J. Bröckelmann, Boris Böll, Daniel Molin, Gundolf Schneider, Sirpa Leppä, Julia Meissner, Peter Kamper, Martin Hutchings, Jacob Haaber Christensen, Ulf Schnetzke, Michael Fuchs, Dennis A Eichenauer, Bastian von Tresckow, Helen Kaul, Peter Borchmann, Alexander Fossa

Blood (2024) 144 (Supplement 1): 3054.

https://doi.org/10.1182/blood-2024-202120

Published: 2024

Journal Articles

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Emil Ramsø Kyvsgaard, Morten Grauslund, Lene Sjö, Linea Melchior, Trine Grantzau, Lise Mette Gjerdrum, Trine Trab, Lærke Sloth Andersen, Anne Ortved Gang, Marie Fredslund Breinholt, Michael Boe Møller, Jacob Haaber Christensen, Thomas Stauffer Larsen, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Kirsten Gronbaek, Martin Hutchings, Simon Husby

Blood (2024) 144 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2024-204772

Published: 2024

Journal Articles

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Mats Jerkeman, Karin Fahl Wader, Ingrid Glimelius, Annika Pasanen, Won Seog Kim, Louise Krüger Hansen, Jon Riise, Martin Hutchings, Hashim Hussein Elhussein, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Mats Ehinger, Klaus Beiske, Rose-Marie Amini, Michael Boe Møller, Marja-Liisa Karjalainen-Lindsberg, Jacob Haaber Christensen

Blood (2024) 144 (Supplement 1): 747.

https://doi.org/10.1182/blood-2024-192939

Published: 2024

Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Blood (2024) 144 (Supplement 1): 883.

https://doi.org/10.1182/blood-2024-199708

Published: 2024

Journal Articles

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Trine Trab, Iman Chanchiri, Ahmed Al-Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Simon Husby, Michael Roost Clausen, Thomas Stauffer Larsen, Andriette C Desseau-Arp, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Kirsten Gronbaek

Blood (2024) 144 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2024-201293

Published: 2024

Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Blood (2024) 144 (Supplement 1): 235.

https://doi.org/10.1182/blood-2024-199710

Published: 2024

Journal Articles

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Sara Rossetti, Sidsel Jacobsen Juul, Frank Eriksson, Peder Emil Warming, Charlotte Glinge, Tarec Christoffer Christoffer El-Galaly, Jacob Haaber Christensen, Peter Kamper, Peter de Nully Brown, Maja Maraldo, Jacob Tfelt-Hansen, Martin Hutchings

Blood (2023) 142 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2023-172989

Published: 2023

Journal Articles

Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients

Rasmus Rask Kragh Jørgensen, Sandra Eloranta, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Soerensen, Peter Kamper, Andrew M Evens, Matthew J. Maurer, Susan K Parsons, Angie Mae Rodday, Jenica Upshaw, Tarec Christoffer Christoffer El-Galaly, Lasse Hjort Jakobsen

Blood (2023) 142 (Supplement 1): 4455.

https://doi.org/10.1182/blood-2023-178498

Published: 2023

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Karin Fahl Wader, Ingrid Glimelius

Blood (2022) 140 (Supplement 1): 184–185.

https://doi.org/10.1182/blood-2022-155654

Published: 2022

Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Blood (2022) 140 (Supplement 1): 1464–1466.

https://doi.org/10.1182/blood-2022-158203

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat

Blood (2022) 140 (Supplement 1): 850–851.

https://doi.org/10.1182/blood-2022-158298

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

Arnon P. Kater, Jacob Haaber Christensen, Hans Herluf Bentzen, Carsten Utoft Niemann, Martin Hutchings, Jenny Chen, Marcia Rios, Tammy Palenski, Tommy Li, Anthony R. Mato

Blood (2021) 138 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2021-146563

Published: 2021

Journal Articles

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

David Belada, Jacob Haaber Christensen, Kristina Drott, Sylvia Snauwaert, Joshua Brody, Mayur Narkhede, Fritz Offner, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi, Michael Roost Clausen

Blood (2021) 138 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2021-146569

Published: 2021

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Amitkumar Mehta, Marek Trněný, Jan Walewski, Vincent Ribrag, Caroline Dartigeas, Jacob Haaber Christensen, Fabrizio Pane, Guillermo Rodriguez, Michal Taszner, Parameswaran Venugopal, Vittorio Ruggero Zilioli, Fred Zheng, Douglas J DeMarini, Wei Jiang, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 382.

https://doi.org/10.1182/blood-2021-147867

Published: 2021

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Amitkumar Mehta, MD, Marek Trněný, MD, Jan Walewski, MD, Vincent Ribrag, MD, Caroline Dartigeas, MD, Jacob Haaber Christensen, MD PhD, Fabrizio Pane, MD, Guillermo Rodríguez, MD, Michal Taszner, MD, Parameswaran Venugopal, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134872

Published: 2020

Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-134398

Published: 2020

NARROW

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only